187 related articles for article (PubMed ID: 34117946)
1. Performance of nanoScan PET/CT and PET/MR for quantitative imaging of
Chomet M; Schreurs M; Vos R; Verlaan M; Kooijman EJ; Poot AJ; Boellaard R; Windhorst AD; van Dongen GA; Vugts DJ; Huisman MC; Beaino W
EJNMMI Res; 2021 Jun; 11(1):57. PubMed ID: 34117946
[TBL] [Abstract][Full Text] [Related]
2. A preclinical PET dual-tracer imaging protocol for ER and HER2 phenotyping in breast cancer xenografts.
Paquette M; Phoenix S; Lawson C; Guérin B; Lecomte R; Tai LH; Turcotte ÉE; Leyton JV
EJNMMI Res; 2020 Jun; 10(1):69. PubMed ID: 32592121
[TBL] [Abstract][Full Text] [Related]
3. Site-specifically labeled
Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for
Vugts DJ; Klaver C; Sewing C; Poot AJ; Adamzek K; Huegli S; Mari C; Visser GWM; Valverde IE; Gasser G; Mindt TL; van Dongen GAMS
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793
[TBL] [Abstract][Full Text] [Related]
5. HER3 PET Imaging:
Rinne SS; Leitao CD; Abouzayed A; Vorobyeva A; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638277
[TBL] [Abstract][Full Text] [Related]
6. In vivo visualization of MET tumor expression and anticalin biodistribution with the MET-specific anticalin 89Zr-PRS-110 PET tracer.
Terwisscha van Scheltinga AG; Lub-de Hooge MN; Hinner MJ; Verheijen RB; Allersdorfer A; Hülsmeyer M; Nagengast WB; Schröder CP; Kosterink JG; de Vries EG; Audoly L; Olwill SA
J Nucl Med; 2014 Apr; 55(4):665-71. PubMed ID: 24614223
[TBL] [Abstract][Full Text] [Related]
7. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
8. CD4
Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
[TBL] [Abstract][Full Text] [Related]
9. Development of [
Ghai A; Zheleznyak A; Mixdorf M; O'Neal J; Ritchey J; Rettig M; DiPersio J; Shokeen M; Achilefu S
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1302-1311. PubMed ID: 33179150
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vivo biodistribution of cells labelled with [
Friberger I; Nilsson JN; Lu L; Siikanen J; Ardenfors O; Milton S; Samén E; Goos JACM; Carlsten M; Holmin S; Tran TA
EJNMMI Res; 2023 Aug; 13(1):73. PubMed ID: 37552341
[TBL] [Abstract][Full Text] [Related]
11. Development and evaluation of
Mohammadpour-Ghazi F; Yousefnia H; Divband G; Zolghadri S; Alirezapour B; Shakeri F
Asia Ocean J Nucl Med Biol; 2023; 11(2):135-144. PubMed ID: 37324228
[TBL] [Abstract][Full Text] [Related]
12. In Vivo Characterization of Platinum(II)-Based Linker Technology for the Development of Antibody-Drug Conjugates: Taking Advantage of Dual Labeling with
Muns JA; Montserrat V; Houthoff HJ; Codée-van der Schilden K; Zwaagstra O; Sijbrandi NJ; Merkul E; van Dongen GAMS
J Nucl Med; 2018 Jul; 59(7):1146-1151. PubMed ID: 29496986
[TBL] [Abstract][Full Text] [Related]
13. ZR-75-1 breast cancer models to study the utility of
Ding Z; Xu X; Li T; Wang J; Sun J; Tang L
Transl Cancer Res; 2021 Mar; 10(3):1430-1438. PubMed ID: 35116468
[TBL] [Abstract][Full Text] [Related]
14.
Giesel FL; Kratochwil C; Lindner T; Marschalek MM; Loktev A; Lehnert W; Debus J; Jäger D; Flechsig P; Altmann A; Mier W; Haberkorn U
J Nucl Med; 2019 Mar; 60(3):386-392. PubMed ID: 30072500
[TBL] [Abstract][Full Text] [Related]
15. Quantitative imaging characteristics of zirconium-89 on Gemini Time-Of-Flight PET/CT.
Alanazi SF; Alzimami KS; Ghannam MM; Aljammaz IJ; Alrumayan F; Sassi SA
Nucl Med Commun; 2016 Dec; 37(12):1238-1245. PubMed ID: 27749774
[TBL] [Abstract][Full Text] [Related]
16. Human Epidermal Growth Factor Receptor 3-Specific Tumor Uptake and Biodistribution of
Warnders FJ; Terwisscha van Scheltinga AGT; Knuehl C; van Roy M; de Vries EFJ; Kosterink JGW; de Vries EGE; Lub-de Hooge MN
J Nucl Med; 2017 Aug; 58(8):1210-1215. PubMed ID: 28360206
[TBL] [Abstract][Full Text] [Related]
17. First Evaluation of PET-Based Human Biodistribution and Dosimetry of
Savi A; Incerti E; Fallanca F; Bettinardi V; Rossetti F; Monterisi C; Compierchio A; Negri G; Zannini P; Gianolli L; Picchio M
J Nucl Med; 2017 Aug; 58(8):1224-1229. PubMed ID: 28209906
[No Abstract] [Full Text] [Related]
18. Total-Body PET and Highly Stable Chelators Together Enable Meaningful
Berg E; Gill H; Marik J; Ogasawara A; Williams S; van Dongen G; Vugts D; Cherry SR; Tarantal AF
J Nucl Med; 2020 Mar; 61(3):453-460. PubMed ID: 31562219
[TBL] [Abstract][Full Text] [Related]
19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
20. Quantitative analysis of MRI-guided attenuation correction techniques in time-of-flight brain PET/MRI.
Mehranian A; Arabi H; Zaidi H
Neuroimage; 2016 Apr; 130():123-133. PubMed ID: 26853602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]